Mineralys Therapeutics, Inc. (MLYS)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch MLYS
See up to 3 months of MLYS. The 7-day demo opens the 1M and 3M ranges and puts MLYS on your watchlist.
Start 7-day demoLatest MLYS insider trades
Jon Congleton - OfficerOpen-market sale$1.91M
About Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. is an SEC registrant, filing under CIK 0001933414, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
MLYS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 8 | 207,219 | $5.67M |
| Grant or award | 2 | 237,400 | |
| Option exercise | 12 | 55,798 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
MLYS insider transactions (Form 4)
11167 Form 4 filings on record, the earliest from Oct 15, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jon Congleton - Officer | Grant or award | Common Stock | 140,900 footnote F1 | $0.00 | - | |
| Jon Congleton - Officer | Grant or award | Stock Option | 187,900 | $0.00 | - | |
| ||||||
| Glenn Sblendorio - Director | Grant or award | Common Stock | 6,200 footnote F1 | $0.00 | - | |
| Glenn Sblendorio - Director | Grant or award | Stock Option | 8,300 | $0.00 | - | |
| ||||||
| Alexander M. Gold - Director | Grant or award | Common Stock | 6,200 footnote F1 | $0.00 | - | |
| Alexander M. Gold - Director | Grant or award | Stock Option | 8,300 | $0.00 | - | |
| ||||||
| Daphne Karydas - Director | Grant or award | Common Stock | 6,200 footnote F1 | $0.00 | - | |
| Daphne Karydas - Director | Grant or award | Stock Option | 8,300 | $0.00 | - | |
| ||||||
| Brian Taylor Slingsby - Director | Grant or award | Common Stock | 6,200 footnote F1 | $0.00 | - | |
| Brian Taylor Slingsby - Director | Other | Common Stock | 6,200 footnote F1 | $0.00 | - | |
| Brian Taylor Slingsby - Director | Other | Common Stock | 6,200 footnote F1 | $0.00 | - | |
| Brian Taylor Slingsby - Director | Grant or award | Stock Option | 8,300 | $0.00 | - | |
| Brian Taylor Slingsby - Director | Other | Stock Option | 8,300 | $0.00 | - | |
| Brian Taylor Slingsby - Director | Other | Stock Option | 8,300 | $0.00 | - | |
| ||||||
 Srinivas Akkaraju - Director | Grant or award | Common Stock | 6,200 footnote F1 | $0.00 | - | |
| Srinivas Akkaraju - Director | Grant or award | Stock Option | 8,300 | $0.00 | - | |
| ||||||
| Derek Dirocco - Director | Grant or award | Common Stock | 6,200 footnote F1 | $0.00 | - | |
| Derek Dirocco - Director | Grant or award | Stock Option | 8,300 | $0.00 | - | |
| ||||||
| David Malcom Rodman - Officer | Grant or award | Common Stock | 38,400 footnote F1 | $0.00 | - | |
| David Malcom Rodman - Officer | Grant or award | Stock Option | 51,300 | $0.00 | - | |
| ||||||
 Adam Scott Levy - Officer | Grant or award | Common Stock | 39,900 footnote F1 | $0.00 | - | |
| Adam Scott Levy - Officer | Grant or award | Stock Option | 53,300 | $0.00 | - | |
| ||||||
| David Malcom Rodman - Officer | Option exercise | Common Stock | 417 | $15.44 | $6K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 417 | $27.59 | $12K | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 417 | $0.00 | - | |
| David Malcom Rodman - Officer | Option exercise | Common Stock | 6,349 | $1.08 | $7K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 5,828 | $28.94 footnote F2 | $169K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 521 | $29.64 footnote F3 | $15K | |
| David Malcom Rodman - Officer | Option exercise | Common Stock | 3,541 | $10.20 | $36K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 3,541 | $27.33 | $97K | |
| David Malcom Rodman - Officer | Option exercise | Common Stock | 4,166 | $14.25 | $59K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 4,166 | $27.33 | $114K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 6,348 | $27.58 footnote F4 | $175K | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 6,349 | $0.00 | - | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 3,541 | $0.00 | - | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 4,166 | $0.00 | - | |
| ||||||
| David Malcom Rodman - Officer | Option exercise | Common Stock | 2,171 | $16.00 | $35K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 2,171 | $30.21 | $66K | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 2,171 | $0.00 | - | |
| David Malcom Rodman - Officer | Option exercise | Common Stock | 416 | $15.44 | $6K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 416 | $32.10 | $13K | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 416 | $0.00 | - | |
| David Malcom Rodman - Officer | Option exercise | Common Stock | 3,542 | $10.20 | $36K | |
| David Malcom Rodman - Officer | Option exercise | Common Stock | 4,167 | $14.25 | $59K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 7,709 | $32.75 | $252K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 11,367 | $32.61 footnote F2 | $371K | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 3,542 | $0.00 | - | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 4,167 | $0.00 | - | |
| ||||||
| Jon Congleton - Officer | Option exercise | Common Stock | 24,082 | $0.54 | $13K | |
| Jon Congleton - Officer | Option exercise | Stock Option | 24,082 | $0.00 | - | |
| Brian Taylor Slingsby - Director | Open-market sale | Common Stock | 1,000,000 | $43.35 | $43.35M | |
| Alexander M. Gold - Director | Option exercise | Stock Option | 15,000 | $0.00 | - | |
| Alexander M. Gold - Director | Option exercise | Stock Option | 6,933 | $0.00 | - | |
| Alexander M. Gold - Director | Option exercise | Stock Option | 2,742 | $0.00 | - | |
| Alexander M. Gold - Director | Option exercise | Stock Option | 10,000 | $0.00 | - | |
| Alexander M. Gold - Director | Option exercise | Common Stock | 15,000 | $10.20 | $153K | |
| Alexander M. Gold - Director | Open-market sale | Common Stock | 10,000 | $42.43 | $424K | |
| Alexander M. Gold - Director | Open-market sale | Common Stock | 5,000 | $47.08 | $235K | |
| Alexander M. Gold - Director | Option exercise | Common Stock | 6,933 | $10.20 | $71K | |
| Alexander M. Gold - Director | Open-market sale | Common Stock | 5,000 | $46.50 | $233K | |
| Alexander M. Gold - Director | Open-market sale | Common Stock | 1,933 | $47.28 | $91K | |
| Alexander M. Gold - Director | Option exercise | Common Stock | 2,742 | $10.20 | $28K | |
| Alexander M. Gold - Director | Option exercise | Common Stock | 10,000 | $12.69 | $127K | |
| Alexander M. Gold - Director | Open-market sale | Common Stock | 12,742 | $46.50 | $593K | |
| Daphne Karydas - Director | Option exercise | Common Stock | 15,000 | $10.20 | $153K | |
| Daphne Karydas - Director | Open-market sale | Common Stock | 10,115 | $45.81 footnote F1 | $463K | |
| Daphne Karydas - Director | Open-market sale | Common Stock | 4,885 | $46.36 footnote F2 | $226K | |
| Daphne Karydas - Director | Option exercise | Stock Option | 15,000 | $0.00 | - | |
| ||||||
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 1,561 | $42.68 footnote F3 | $67K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 12,952 | $41.65 footnote F4 | $539K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 8,485 | $42.34 footnote F5 | $359K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 4,142 | $43.50 footnote F6 | $180K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 8,456 | $45.18 footnote F7 | $382K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 38,900 | $45.93 footnote F8 | $1.79M | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 32,718 | $46.88 footnote F9 | $1.53M | |
| Adam Scott Levy - Officer | Option exercise | Stock Option | 20,547 | $0.00 | - | |
| Adam Scott Levy - Officer | Option exercise | Stock Option | 34,414 | $0.00 | - | |
| Adam Scott Levy - Officer | Option exercise | Stock Option | 44,079 | $0.00 | - | |
| Adam Scott Levy - Officer | Option exercise | Stock Option | 6,613 | $0.00 | - | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 11,295 | $41.87 footnote F2 | $473K | |
| Adam Scott Levy - Officer | Option exercise | Common Stock | 34,414 | $16.00 | $551K | |
| Adam Scott Levy - Officer | Option exercise | Common Stock | 44,079 | $14.25 | $628K | |
| Adam Scott Levy - Officer | Option exercise | Common Stock | 6,613 | $15.44 | $102K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 1,015 | $42.00 | $43K | |
| Adam Scott Levy - Officer | Option exercise | Common Stock | 20,547 | $10.20 | $210K | |
| ||||||
| Jon Congleton - Officer | Open-market sale | Common Stock | 12,806 | $41.64 footnote F1 | $533K | |
| Jon Congleton - Officer | Open-market sale | Common Stock | 8,862 | $42.31 footnote F2 | $375K | |
| Jon Congleton - Officer | Open-market sale | Common Stock | 4,000 | $43.50 footnote F3 | $174K | |
| Jon Congleton - Officer | Open-market sale | Common Stock | 29,207 | $45.20 footnote F4 | $1.32M | |
| Jon Congleton - Officer | Open-market sale | Common Stock | 112,275 | $45.83 footnote F5 | $5.15M | |
| Jon Congleton - Officer | Open-market sale | Common Stock | 32,850 | $46.89 footnote F6 | $1.54M | |
| ||||||
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 10,369 | $43.01 footnote F2 | $446K | |
| ||||||
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 7,366 | $41.90 footnote F2 | $309K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 3,392 | $42.26 footnote F4 | $143K | |
| ||||||
| Jon Congleton - Officer | Open-market sale | Common Stock | 13,548 | $42.63 footnote F2 | $578K | |
| Jon Congleton - Officer | Open-market sale | Common Stock | 1,552 | $43.03 footnote F3 | $67K | |
| ||||||
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 9,302 | $35.90 | $334K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 2,065 | $36.47 | $75K | |
| Srinivas Akkaraju | Open-market purchase | Common Stock | 588,235 | $25.50 | $15.00M | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 1,176,470 | $25.50 | $30.00M | |
| David Malcom Rodman - Officer | Option exercise | Common Stock | 6,349 | $1.08 | $7K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 11,365 | $12.93 | $147K | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 6,349 | $0.00 | - | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 12,946 | $14.04 | $182K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 807 | $14.00 | $11K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 51,500 | $14.70 | $757K | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 8,425 | $15.10 | $127K | |
| David Malcom Rodman - Officer | Option exercise | Common Stock | 6,349 | $1.08 | $7K | |
| David Malcom Rodman - Officer | Open-market sale | Common Stock | 11,366 | $14.59 | $166K | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 6,349 | $0.00 | - | |
| Adam Scott Levy - Officer | Open-market sale | Common Stock | 10,758 | $14.45 | $155K | |
Item 2.02, 5.02, 9.01
Item 8.01, 9.01
Item 1.01, 2.03
Item 5.07, 9.01
Recent MLYS Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Rodman David Malcom | Officer | 3,542 | $78K | View on EDGAR | |
| Congleton Jon | Officer, Director | 75,000 |
MLYS insider trading FAQ
What is the latest insider trade for MLYS?
Mineralys Therapeutics, Inc. (MLYS) had 9 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for MLYS runs to 67 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying MLYS stock?
No insider purchases of MLYS were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling MLYS stock?
8 insider sales of MLYS were filed in the last 90 days, totaling $5.67M.
Where can I see MLYS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects MLYS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jon Congleton view on EDGAR
- - Brian Taylor Slingsby view on EDGAR
- - Eric Warren view on EDGAR
- - Daphne Karydas view on EDGAR
- - Eric Warren view on EDGAR
- - James J. Ferguson III view on EDGAR
- - David Malcom Rodman view on EDGAR
- - Eric Warren view on EDGAR
- - David Malcom Rodman view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where MLYS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow MLYS with a 7-day demo
- MLYS on your watchlist
- Every MLYS Form 4 filing on record
- Up to 3 months of MLYS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
